Why National Health Investors is on investors’ radar today

National Health Investors (NHI) has drawn attention after recent trading left the stock with a month return of a 6.3% decline and a past 3 months return of a 2.8% decline.

Against that backdrop, the shares last closed at US$77.00, with a market value of about US$3.7b. For investors tracking longer timelines, total return over the past year stands at 7.5%, with a 3 year total return of about 0.84x and a 5 year total return of about 0.39x.

Recent trading has been weak, with a 7 day share price return of a 9.3% decline and a 30 day share price return of a 6.3% decline. However, longer term total shareholder returns have been positive, suggesting momentum has cooled after a stronger multi year period.

If you want to see what else is moving in related areas of the market, this could be a good time to scan senior care and real estate peers using a discovery focused screener such as 18 top founder-led companies

With NHI trading at US$77.00, carrying a value score of 4 and an estimated 55% intrinsic discount, plus a 15% gap to analyst targets, the key question is whether this indicates a potential opportunity or whether markets are already fully reflecting the outlook in the current price.

Most Popular Narrative: 13.5% Undervalued

With National Health Investors trading at $77.00 against a widely followed fair value estimate of $89.00, the prevailing narrative sees the current price as below intrinsic value, built on specific assumptions about future growth and profitability.

NHI's focused expansion of its SHOP (Senior Housing Operating Portfolio) segment, with double-digit NOI growth projected and a robust pipeline of accretive acquisitions, positions the company for outsized multi-year NOI and earnings growth relative to peers.

Curious what earnings and revenue profile sits behind that fair value gap? The narrative leans on rising margins, faster top line growth and a richer future P/E multiple. The full story ties those moving parts together into one valuation blueprint.

If you want to see how those assumptions stack up across growth, profitability and valuation, the most widely followed narrative pulls everything together in one place for National Health Investors, with its fair value estimate anchored at $89.00 and built using a 7.44% discount rate.

Result: Fair Value of $89 (UNDERVALUED)

However, that fair value story depends on the SHOP portfolio avoiding further occupancy softness and on tenant concentration not turning isolated operator issues into broader earnings pressure.

Next Steps

Given the mix of risks and rewards in this story, consider whether the current price aligns with the fundamentals. Take a closer look at both sides and review the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that fit your goals, so widen your search and let the data do the heavy lifting.

• Target robust cash generation and valuation support by checking companies screened as 54 high quality undervalued stocks that might deserve a closer look.
• Prioritize resilience and capital protection by reviewing 72 resilient stocks with low risk scores and spotting businesses with more measured risk profiles.
• Hunt for quality stories off the mainstream radar by scanning the screener containing 25 high quality undiscovered gems that meet strict fundamental filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.